MedTrace Logo

Safety and Tolerability of Z-100 in Patients With Early HIV Infection

NCT00016692 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2006-04-27

No results posted yet for this study

Summary

The purpose of the study is to see if Z-100 (an investigational drug) treatment is safe in HIV patients who have never received treatment for their HIV, who have not been taking highly active antiretroviral therapy (HAART) for at least 8 weeks, or who have been stable on their current first or second HAART regimen for at least 12 weeks.

Conditions

  • HIV Infections

Interventions

DRUG

Z-100

Sponsors & Collaborators

  • Zeria Pharmaceutical

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00016692 on ClinicalTrials.gov